Trade DexCom, Inc. - DXCM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.24 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Dexcom Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 139.39 |
Open* | 139.67 |
1-Year Change* | 20.54% |
Day's Range* | 138.57 - 140.39 |
52 wk Range | 74.75-139.55 |
Average Volume (10 days) | 2.76M |
Average Volume (3 months) | 76.54M |
Market Cap | 49.24B |
P/E Ratio | 144.33 |
Shares Outstanding | 386.37M |
Revenue | 3.40B |
EPS | 0.88 |
Dividend (Yield %) | N/A |
Beta | 1.20 |
Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 139.39 | -1.75 | -1.24% | 141.14 | 141.42 | 137.86 |
Mar 26, 2024 | 139.81 | -0.77 | -0.55% | 140.58 | 141.52 | 138.33 |
Mar 25, 2024 | 140.00 | 6.72 | 5.04% | 133.28 | 140.67 | 133.12 |
Mar 22, 2024 | 133.08 | 0.59 | 0.45% | 132.49 | 134.20 | 131.11 |
Mar 21, 2024 | 133.31 | 1.02 | 0.77% | 132.29 | 136.14 | 132.29 |
Mar 20, 2024 | 132.40 | -1.30 | -0.97% | 133.70 | 135.19 | 131.16 |
Mar 19, 2024 | 134.06 | 0.37 | 0.28% | 133.69 | 134.25 | 131.36 |
Mar 18, 2024 | 134.61 | 3.95 | 3.02% | 130.66 | 135.48 | 130.66 |
Mar 15, 2024 | 130.39 | 0.85 | 0.66% | 129.54 | 131.51 | 128.45 |
Mar 14, 2024 | 129.44 | -2.34 | -1.78% | 131.78 | 132.39 | 128.63 |
Mar 13, 2024 | 131.56 | -3.90 | -2.88% | 135.46 | 137.23 | 131.42 |
Mar 12, 2024 | 135.27 | 3.33 | 2.52% | 131.94 | 136.62 | 130.19 |
Mar 11, 2024 | 132.95 | -1.21 | -0.90% | 134.16 | 135.97 | 132.93 |
Mar 8, 2024 | 135.17 | 1.59 | 1.19% | 133.58 | 136.09 | 132.02 |
Mar 7, 2024 | 133.12 | -2.18 | -1.61% | 135.30 | 137.66 | 132.15 |
Mar 6, 2024 | 133.61 | 7.66 | 6.08% | 125.95 | 133.81 | 123.94 |
Mar 5, 2024 | 121.71 | -0.72 | -0.59% | 122.43 | 123.48 | 120.69 |
Mar 4, 2024 | 122.23 | 0.70 | 0.58% | 121.53 | 124.12 | 120.42 |
Mar 1, 2024 | 121.69 | 7.68 | 6.74% | 114.01 | 122.14 | 113.36 |
Feb 29, 2024 | 114.94 | 0.29 | 0.25% | 114.65 | 115.43 | 113.87 |
DexCom, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, April 25, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Dexcom Inc Earnings Release Q1 2024 Dexcom Inc Earnings ReleaseForecast -Previous - |
Friday, May 17, 2024 | ||
Time (UTC) 21:00 | Country US
| Event DexCom Inc Annual Shareholders Meeting DexCom Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2909.8 | 2448.5 | 1926.7 | 1476 | 1031.6 |
Revenue | 2909.8 | 2448.5 | 1926.7 | 1476 | 1031.6 |
Cost of Revenue, Total | 1012.8 | 739.9 | 622.2 | 530.4 | 367.7 |
Gross Profit | 1897 | 1708.6 | 1304.5 | 945.6 | 663.9 |
Total Operating Expense | 2518.6 | 2182.8 | 1627.2 | 1333.7 | 1217.9 |
Selling/General/Admin. Expenses, Total | 1000.2 | 806.8 | 618.2 | 515.7 | 432.8 |
Research & Development | 484.2 | 604.2 | 359.9 | 273.5 | 417.4 |
Operating Income | 391.2 | 265.7 | 299.5 | 142.3 | -186.3 |
Interest Income (Expense), Net Non-Operating | -0.4 | -8.9 | -1.6 | -38.1 | 59.8 |
Other, Net | |||||
Net Income Before Taxes | 390.8 | 256.8 | 297.9 | 104.2 | -126.5 |
Net Income After Taxes | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Net Income Before Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Net Income | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Income Available to Common Excl. Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.5 |
Income Available to Common Incl. Extra. Items | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Diluted Net Income | 341.2 | 216.9 | 549.7 | 101.1 | -127.1 |
Diluted Weighted Average Shares | 427.5 | 428.8 | 420.4 | 369.2 | 352.8 |
Diluted EPS Excluding Extraordinary Items | 0.79813 | 0.50583 | 1.30756 | 0.27384 | -0.36139 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 0.83101 | 0.60964 | 1.36632 | 0.33848 | -0.35145 |
Total Extraordinary Items | 0 | 0.4 | |||
Unusual Expense (Income) | 13.9 | 28.2 | 24.4 | 14.1 | |
Depreciation / Amortization | 7.5 | 3.7 | 2.5 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 975 | 871.3 | 741.5 | 815.2 | 769.6 |
Revenue | 975 | 871.3 | 741.5 | 815.2 | 769.6 |
Cost of Revenue, Total | 351.7 | 324.9 | 278.9 | 260 | 275.4 |
Gross Profit | 623.3 | 546.4 | 462.6 | 555.2 | 494.2 |
Total Operating Expense | 769.5 | 743.2 | 694.3 | 689.8 | 622.1 |
Selling/General/Admin. Expenses, Total | 284.7 | 297.3 | 294.6 | 297.8 | 234.6 |
Research & Development | 131.4 | 119.3 | 119 | 116.3 | 110.3 |
Operating Income | 205.5 | 128.1 | 47.2 | 125.4 | 147.5 |
Interest Income (Expense), Net Non-Operating | 1 | 31.2 | 17.3 | 7.8 | -1.3 |
Net Income Before Taxes | 240.4 | 159.3 | 64.5 | 133.2 | 146.2 |
Net Income After Taxes | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Net Income Before Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Net Income | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Income Available to Common Excl. Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Income Available to Common Incl. Extra. Items | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Diluted Net Income | 120.7 | 115.9 | 48.6 | 91.8 | 101.2 |
Diluted Weighted Average Shares | 426.8 | 431.5 | 418.5 | 426 | 425.8 |
Diluted EPS Excluding Extraordinary Items | 0.2828 | 0.2686 | 0.11613 | 0.21549 | 0.23767 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.2828 | 0.2686 | 0.11613 | 0.23798 | 0.23767 |
Unusual Expense (Income) | 13.9 | ||||
Depreciation / Amortization | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 |
Other, Net | 33.9 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 3668.8 | 3684.4 | 3424.8 | 1969.4 | 1699.5 |
Cash and Short Term Investments | 2456.2 | 2731.2 | 2707.7 | 1533.3 | 1385.6 |
Cash & Equivalents | 642.3 | 1052.6 | 817.6 | 446.2 | 1137 |
Short Term Investments | 1813.9 | 1678.6 | 1890.1 | 1087.1 | 248.6 |
Total Receivables, Net | 713.3 | 514.3 | 428.5 | 286.3 | 226.7 |
Accounts Receivable - Trade, Net | 713.3 | 514.3 | 428.5 | 286.3 | 226.7 |
Total Inventory | 306.7 | 357.3 | 234.7 | 119.8 | 70.7 |
Prepaid Expenses | 192.6 | 81.6 | 53.9 | 30 | 16.5 |
Total Assets | 5391.7 | 4933.3 | 4290.5 | 2395 | 1916 |
Property/Plant/Equipment, Total - Net | 1135.6 | 889.9 | 608.6 | 392.8 | 183.1 |
Property/Plant/Equipment, Total - Gross | 1498.8 | 1121.4 | 762.8 | 497.8 | 262.9 |
Accumulated Depreciation, Total | -363.2 | -231.5 | -154.2 | -105 | -79.8 |
Goodwill, Net | 25.7 | 26.5 | 19.3 | 18.6 | 18.7 |
Intangibles, Net | 173.3 | 31.5 | |||
Other Long Term Assets, Total | 388.3 | 301 | 237.8 | 14.2 | 14.7 |
Total Current Liabilities | 1839.3 | 720.8 | 614.1 | 360.2 | 222.4 |
Accounts Payable | 237.9 | 189.4 | 163.3 | 102.3 | 75.5 |
Accrued Expenses | 814.5 | 514.3 | 439.8 | 255.6 | 144 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 776.8 | 8.8 | 0.6 | ||
Other Current Liabilities, Total | 10.1 | 17.1 | 2.2 | 1.7 | 2.9 |
Total Liabilities | 3259.9 | 2891.2 | 2464 | 1512.4 | 1252.7 |
Total Long Term Debt | 1257.3 | 2038.8 | 1721.2 | 1074.1 | 1017.6 |
Long Term Debt | 1197.7 | 1981.8 | 1667.2 | 1059.7 | 1010.3 |
Capital Lease Obligations | 59.6 | 57 | 54 | 14.4 | 7.3 |
Other Liabilities, Total | 158.4 | 125.7 | 128.7 | 78.1 | 12.7 |
Total Equity | 2131.8 | 2042.1 | 1826.5 | 882.6 | 663.3 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 2258.1 | 2109 | 2125.3 | 1675.9 | 1560.6 |
Retained Earnings (Accumulated Deficit) | 479.9 | 138.7 | -202.1 | -695.7 | -798.9 |
Other Equity, Total | -11.6 | 0.5 | 3.2 | 2.3 | 1.5 |
Total Liabilities & Shareholders’ Equity | 5391.7 | 4933.3 | 4290.5 | 2395 | 1916 |
Total Common Shares Outstanding | 386.3 | 388 | 384.4 | 366.4 | 360 |
Treasury Stock - Common | -595 | -206.2 | -100 | -100 | -100 |
Deferred Income Tax | 4.9 | 5.9 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 4698.4 | 5002.9 | 3767.4 | 3668.8 | 3398.5 |
Cash and Short Term Investments | 3240.3 | 3636.2 | 2567 | 2456.2 | 2371.9 |
Cash & Equivalents | 643.7 | 1194.9 | 623.2 | 642.3 | 698.1 |
Short Term Investments | 2596.6 | 2441.3 | 1943.8 | 1813.9 | 1673.8 |
Total Receivables, Net | 785.7 | 755.6 | 652.5 | 713.3 | 564.1 |
Accounts Receivable - Trade, Net | 785.7 | 750.6 | 636.8 | 713.3 | 564.1 |
Total Inventory | 498.6 | 421.1 | 366 | 306.7 | 311 |
Prepaid Expenses | 173.8 | 190 | 181.9 | 192.6 | 151.5 |
Total Assets | 6596.2 | 6820.7 | 5515.9 | 5391.7 | 4899.2 |
Property/Plant/Equipment, Total - Net | 1152.3 | 1153.9 | 1153.5 | 1135.6 | 1075.6 |
Property/Plant/Equipment, Total - Gross | 1618.6 | 1582.2 | 1548 | 1498.8 | 1414.1 |
Accumulated Depreciation, Total | -466.3 | -428.3 | -394.5 | -363.2 | -338.5 |
Goodwill, Net | 25.3 | 25.8 | 25.7 | 25.7 | 24.7 |
Other Long Term Assets, Total | 575.7 | 483.9 | 405.7 | 388.3 | 376 |
Total Current Liabilities | 1678.6 | 2069.7 | 1865 | 1839.3 | 900.5 |
Accounts Payable | 242.4 | 269.1 | 266.2 | 237.9 | 198.1 |
Accrued Expenses | 1303 | 1017.8 | 816 | 818.7 | 699.7 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 9 | 9 | 9.6 | 10.1 | 2.7 |
Total Liabilities | 4328.3 | 4720.3 | 3282.9 | 3259.9 | 3074.7 |
Total Long Term Debt | 2490.3 | 2489.1 | 1257.7 | 1257.3 | 2029.2 |
Long Term Debt | 2432.4 | 2430.6 | 1198.5 | 1197.7 | 1968.8 |
Capital Lease Obligations | 57.9 | 58.5 | 59.2 | 59.6 | 60.4 |
Other Liabilities, Total | 154.8 | 156.7 | 155.4 | 158.4 | 139.7 |
Total Equity | 2267.9 | 2100.4 | 2233 | 2131.8 | 1824.5 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
Additional Paid-In Capital | 3618 | 2269 | 2305.6 | 2258.1 | 2072.1 |
Retained Earnings (Accumulated Deficit) | 765.1 | 644.4 | 528.5 | 479.9 | 388.1 |
Treasury Stock - Common | -2080 | -784.1 | -595 | -595 | -595 |
Other Equity, Total | -35.6 | -29.3 | -6.5 | -11.6 | -41.1 |
Total Liabilities & Shareholders’ Equity | 6596.2 | 6820.7 | 5515.9 | 5391.7 | 4899.2 |
Total Common Shares Outstanding | 386.4 | 386.1 | 387.6 | 386.3 | 386.2 |
Intangibles, Net | 144.5 | 154.2 | 163.6 | 173.3 | 24.4 |
Deferred Income Tax | 4.6 | 4.8 | 4.8 | 4.9 | 5.3 |
Current Port. of LT Debt/Capital Leases | 124.2 | 773.8 | 773.2 | 772.6 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 341.2 | 154.7 | 493.6 | 101.1 | -127.1 |
Cash From Operating Activities | 669.5 | 442.5 | 475.6 | 314.5 | 123.2 |
Cash From Operating Activities | 155.9 | 102 | 67.1 | 48.7 | 29.1 |
Non-Cash Items | 167.3 | 322.7 | 213 | 158.6 | 262.1 |
Cash Taxes Paid | 114.2 | 16.8 | 3.6 | 4.8 | 2.3 |
Cash Interest Paid | 12.2 | 11.6 | 10.6 | 10.4 | 3.6 |
Changes in Working Capital | 26.7 | -132 | -20.8 | 6.1 | -40.9 |
Cash From Investing Activities | -521.5 | -216.1 | -1018 | -1015.2 | -139.8 |
Capital Expenditures | -364.8 | -389.2 | -199 | -180 | -67.1 |
Other Investing Cash Flow Items, Total | -156.7 | 173.1 | -819 | -835.2 | -72.7 |
Cash From Financing Activities | -552.5 | 10.4 | 912.1 | 10.7 | 710.4 |
Issuance (Retirement) of Stock, Net | -535.2 | 20.3 | 15.3 | 11.9 | 94.6 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 906.2 | 0 | 617.7 |
Net Change in Cash | -410.3 | 235.4 | 371.8 | -690.7 | 695.6 |
Foreign Exchange Effects | -5.8 | -1.4 | 2.1 | -0.7 | 1.8 |
Financing Cash Flow Items | -17.3 | -9.9 | -9.4 | -1.2 | -1.9 |
Deferred Taxes | -21.6 | -4.9 | -277.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 48.6 | 341.2 | 249.4 | 148.2 | 97.3 |
Cash From Operating Activities | 155.4 | 669.5 | 537 | 243.8 | 71 |
Cash From Operating Activities | 41.6 | 155.9 | 119.6 | 80.4 | 36.8 |
Deferred Taxes | -9.3 | -21.6 | -53.6 | -19.8 | 0.1 |
Non-Cash Items | 23 | 167.3 | 128.9 | 80.7 | 34.3 |
Changes in Working Capital | 51.5 | 26.7 | 92.7 | -45.7 | -97.5 |
Cash From Investing Activities | -186.7 | -521.5 | -327.4 | -556.7 | -411.8 |
Capital Expenditures | -74.7 | -364.8 | -301.3 | -193.1 | -101.6 |
Other Investing Cash Flow Items, Total | -112 | -156.7 | -26.1 | -363.6 | -310.2 |
Cash From Financing Activities | 11.2 | -552.5 | -551.5 | 1 | 5.3 |
Financing Cash Flow Items | -1.1 | -17.3 | -16.3 | -9.1 | -4.8 |
Issuance (Retirement) of Stock, Net | 12.3 | -535.2 | -535.2 | 10.1 | 10.1 |
Foreign Exchange Effects | 1.1 | -5.8 | -12.6 | -5.3 | -1 |
Net Change in Cash | -19 | -410.3 | -354.5 | -317.2 | -336.5 |
Issuance (Retirement) of Debt, Net | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
DexCom Company profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.Industry: | Medical Equipment, Supplies & Distribution (NEC) |
6340 Sequence Dr
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com